What is the recommended evaluation and management for a patient with diffuse sensory peripheral neuropathy identified on electromyography (EMG)?

Evaluation and Management of Diffuse Sensory Peripheral Neuropathy on EMG

For a patient with diffuse sensory peripheral neuropathy confirmed on EMG, focus your evaluation on identifying treatable causes through targeted laboratory testing (blood glucose, vitamin B12 with metabolites, and serum protein immunofixation electrophoresis), and initiate symptomatic treatment with first-line agents: duloxetine, gabapentin/pregabalin, or tricyclic antidepressants. 1, 2

Initial Diagnostic Workup

Essential Laboratory Tests (Highest Yield)

The three tests with the highest diagnostic yield should be ordered first 1, 2:

• Blood glucose or HbA1c - Diabetes accounts for >50% of peripheral neuropathy cases 3
• Vitamin B12 with metabolites (methylmalonic acid ± homocysteine) - Identifies reversible B12 deficiency 1, 2
• Serum protein immunofixation electrophoresis - More sensitive than standard SPEP for detecting monoclonal gammopathies, which occur in 10% of otherwise unexplained neuropathy 1

Additional Testing for Glucose Metabolism

If fasting glucose is borderline, consider glucose tolerance testing (GTT), as 25-36% of patients with idiopathic sensory neuropathy have impaired glucose tolerance (pre-diabetes), particularly those with painful symptoms 1

Exclude Other Treatable Causes

Evaluate for 1:

• Toxins: Alcohol use history, neurotoxic medication exposure (chemotherapy, amiodarone, HIV medications)
• Hypothyroidism: TSH level
• Renal disease: Comprehensive metabolic panel
• Nutritional deficiencies: Beyond B12, consider other B vitamins if indicated
• Infections: HIV testing if risk factors present
• Autoimmune conditions: Consider if atypical features present

When to Refer to Neurology

Electrophysiological testing beyond standard EMG is rarely needed except when 1:

• Clinical features are atypical (asymmetric, rapid progression, motor predominance)
• Suspicion for hereditary neuropathy (family history, young age, foot deformities)
• Demyelinating pattern on EMG (dramatically narrows differential) 4
• Consideration of nerve or skin biopsy for small fiber neuropathy 1

Symptomatic Pain Management

First-Line Pharmacologic Options

Choose ONE of the following based on comorbidities and contraindications 1, 3:

Option 1: Duloxetine (SNRI)

• Dosing: 60-120 mg daily 1
• Evidence: FDA-approved for diabetic neuropathy; 38% achieve ≥50% pain reduction 1, 3
• Contraindications: Hepatic disease 1
• Advantages: Also treats comorbid depression

Option 2: Gabapentin or Pregabalin (α2-δ ligands)

• Gabapentin: 300-1,200 mg three times daily 1
• Pregabalin: 100 mg three times daily (FDA-approved for diabetic neuropathy) 1
• Contraindications: Caution with edema, unsteadiness/falls 1
• Titration: Start low, increase gradually over weeks

Option 3: Tricyclic Antidepressants

• Nortriptyline or desipramine: 25-75 mg at bedtime (preferred over amitriptyline due to fewer anticholinergic effects) 1
• Amitriptyline: 10-75 mg at bedtime 1
• Number needed to treat: 1.5-3.5 1
• Contraindications: Glaucoma, orthostatic hypotension, cardiovascular disease, age >40 years requires screening ECG 1
• Maximum dose: <100 mg/day due to cardiac toxicity risk 1
• Titration: Start 10 mg/day, especially in elderly; adequate trial requires 6-8 weeks 1

Second-Line and Combination Therapy

If inadequate response after adequate trial of first-line monotherapy 1:

• Add a different first-line agent from another class (e.g., combine duloxetine with gabapentin)
• Consider opioids (tramadol 200-400 mg/day, oxycodone 20-80 mg/day) for severe pain or acute exacerbations 1
• Topical agents: Capsaicin cream 0.025-0.075% applied 3-4 times daily for localized pain 1

Important Caveats

• No disease-modifying treatments exist - all pharmacologic interventions are symptomatic only and do not reverse nerve damage 1
• Glycemic control in diabetics may slow progression but does not reverse neuronal loss 1
• Up to 50% of neuropathy may be asymptomatic - pain treatment is only for symptomatic patients 1

Non-Pharmacologic Management

Foot Care Education (Critical for Preventing Morbidity)

All patients with sensory neuropathy require 1:

• Daily foot inspection for injuries (visual and manual palpation to substitute for lost sensation)
• Annual 10-g monofilament testing to identify feet at risk for ulceration and amputation 1
• Proper footwear: Well-fitted shoes; therapeutic footwear for those with increased plantar pressure or bony deformities 1
• Professional foot care: Regular podiatry for callus debridement and nail care

Autonomic Neuropathy Screening

Screen for autonomic symptoms that may require specific management 1:

• Orthostatic hypotension (resting tachycardia, dizziness on standing)
• Gastroparesis (erratic glucose control, early satiety, nausea)
• Bladder dysfunction
• Erectile dysfunction
• Sudomotor dysfunction (abnormal sweating)

Expected Outcomes and Prognosis

Complete reversal of nerve damage is uncommon even with treatment of underlying causes 3. Management goals focus on:

• Preventing progression through treatment of underlying etiology
• Reducing pain to improve quality of life (realistic goal: ≥30-50% pain reduction) 1, 3
• Preventing complications (foot ulcers, falls, autonomic crises)

Idiopathic neuropathy accounts for 25-46% of cases after complete evaluation and should be considered a diagnosis of exclusion 2, 3.